BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $2.56 Million Stock Holdings in DaVita Inc. $DVA

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lowered its stake in DaVita Inc. (NYSE:DVA) by 77.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,801 shares of the company’s stock after selling 67,046 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in DaVita were worth $2,563,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. KBC Group NV grew its position in DaVita by 38.7% during the 2nd quarter. KBC Group NV now owns 374,749 shares of the company’s stock worth $53,383,000 after acquiring an additional 104,554 shares during the last quarter. Nordea Investment Management AB boosted its stake in shares of DaVita by 1.8% during the third quarter. Nordea Investment Management AB now owns 286,585 shares of the company’s stock valued at $37,864,000 after purchasing an additional 5,193 shares in the last quarter. Man Group plc grew its holdings in shares of DaVita by 1,608.6% during the second quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after purchasing an additional 269,081 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of DaVita by 132.1% during the second quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock worth $37,619,000 after purchasing an additional 150,318 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC increased its stake in shares of DaVita by 49.1% in the second quarter. Worldquant Millennium Advisors LLC now owns 257,845 shares of the company’s stock valued at $36,730,000 after buying an additional 84,859 shares during the period. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Down 0.4%

Shares of DVA stock opened at $147.12 on Friday. The firm has a 50 day moving average of $120.13 and a 200-day moving average of $125.20. The company has a market cap of $9.83 billion, a price-to-earnings ratio of 14.85, a price-to-earnings-growth ratio of 0.52 and a beta of 0.99. DaVita Inc. has a 52 week low of $101.00 and a 52 week high of $157.12.

DaVita (NYSE:DVA) last released its earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.24 by $0.16. The company had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. DaVita’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current year.

Wall Street Analyst Weigh In

DVA has been the topic of a number of research reports. TD Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. UBS Group boosted their price objective on shares of DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Truist Financial set a $158.00 target price on DaVita in a research report on Thursday, February 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research report on Monday, December 29th. Finally, Zacks Research upgraded DaVita from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $160.50.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.